Relacorilant
Relacorilant improves cardiometabolic metrics for patients with Cushing’s syndrome
Among patients with endogenous hypercortisolism, relacorilant improved cardiometabolic parameters such as blood pressure, HbA1c and weight, according to results of a long-term extension study.
Top in endocrinology: New OTC glucose monitors; exposure to endocrine-disrupting chemicals
The FDA recently cleared two over-the-counter continuous glucose monitoring systems, one for adults with type 2 diabetes who do not use insulin and another for adults without diabetes who are looking to improve overall health and wellness.
Relacorilant tied to sustained cardiometabolic improvements in Cushing’s syndrome
PHILADELPHIA — Adults with Cushing’s syndrome who responded to relacorilant had sustained improvements in blood pressure and glucose levels through 34 weeks, according to findings from a phase 3 trial.
Relacorilant lowers odds for loss of BP control for adults with Cushing’s syndrome
A selective cortisol modulator was linked to lower odds for loss of blood pressure control among adults with Cushing’s syndrome compared with placebo, according to topline results from a phase 3 trial.
Relacorilant regimen prolongs survival in recurrent platinum-resistant ovarian cancer
CHICAGO — Intermittent relacorilant plus nab-paclitaxel demonstrated an OS benefit among women with recurrent platinum-resistant/refractory ovarian cancer compared with nab-paclitaxel alone.